Immunova to Acquire AlphaTON Subsidiary Iox Therapeutics
Immunova has moved to acquire AlphaTON's cancer-treatment subsidiary, Iox Therapeutics, in a deal that signals a stra...
Identify the major factors influencing funding timing and practical steps to optimize speed from approval to disbursement.
16,493 articlesImmunova has moved to acquire AlphaTON's cancer-treatment subsidiary, Iox Therapeutics, in a deal that signals a stra...
A single quarterly filing can rewrite a fund’s star players. Tepper’s Appaloosa appears to have shifted away from NVI...
Bitdeer, a leading Bitcoin miner, has sold its entire BTC stash, signaling a strategic pivot that could influence nea...
The Old-Age and Survivors Insurance fund faces insolvency by 2032, threatening automatic benefit adjustments unless l...
OpenAI wins a Pentagon deal to deploy its AI in classified systems as Anthropic is designated a supply chain risk by ...
Analysts warn that electrifying AI data centers by 2030 could require $1.4 trillion in investment, driven by surging ...
The quantum race isn’t just about flashy qubit players. The real upside sits in the infrastructure that makes quantum...
February brought a sharp move for Applied Digital, with the stock sliding around 19%. This article breaks down what d...
A near-40 couple with $86,000 in debt is told they can still reach millions in retirement after paying off debt and p...
Institutional investors are quietly reshaping the landscape of net-lease REITs. A notable stake in Agree Realty signa...
As geopolitical tensions flare, investors ask whether they should sell avoid) conflict XRP. This guide breaks down ri...
Today’s session showed a rally fade for Plug Power and a broader pullback in hydrogen names. This article breaks down...